CircRNAs act as signaling hubs for immune checkpoints and indicators of ICI response in lymphoma
CircRNAs May Help Predict Response to Lymphoma Immunotherapy
This systematic review examines the role of circRNAs, including EBV-encoded types, in immune evasion within lymphomas. The authors conclude …
New research suggests that specific molecules called circRNAs could help doctors predict how patients with lymphoma will respond to immune c…
Spatial immune niches provide a framework for understanding immunotherapy resistance in gastric cancer
Spatial Immune Niches May Help Explain Gastric Cancer Treatment Response
This narrative review synthesizes diverse data types to identify spatial immune niches as key determinants of immunotherapy response in gast…
New research into spatial immune niches suggests a way to better understand why some patients with gastric cancer respond to immunotherapy.
Pretreatment sarcopenia and low PNI are associated with worse survival in ICI-treated HNSCC
Muscle Loss and Nutrition Linked to Survival in Head Cancer
This meta-analysis evaluates the prognostic impact of CT-based sarcopenia and nutritional indices on overall survival in patients with recur…
Low muscle mass and poor nutritional status are linked to worse survival outcomes for patients with advanced head and neck cancer.
ICI Safety in Early Breast Cancer: Meta-Analysis of 3977 Patients
Immune checkpoint inhibitors show specific side effects in early breast cancer
Meta-analysis of 3977 early breast cancer patients shows ICIs add manageable toxicity, with alopecia and leukopenia most common, and endocri…
New data highlights common and severe side effects for patients with early-stage breast cancer using immune checkpoint inhibitor treatments.
Immune checkpoint inhibitors show higher rates of high-grade immune-related adverse events in cervical cancer
Immune checkpoint inhibitors show specific safety risks in cervical cancer
This meta-analysis of 3302 patients with cervical cancer evaluated the safety profile of immune checkpoint inhibitors (ICIs) compared to sta…
New analysis shows that while some side effects of immune checkpoint inhibitors are similar to standard care, certain high grade immune reac…
CD73-adenosine axis serves as a metabolic immune checkpoint and potential target to overcome melanoma resistance
CD73 Target May Help Overcome Melanoma Treatment Resistance
This systematic review examines the role of the CD73-adenosine axis in advanced melanoma and its implications for treatment resistance. The …
New research explores how blocking the CD73-adenosine axis could help patients with advanced melanoma overcome resistance to current treatme…
Chemo combinations with ivonescimab, sacituzumab tirumotecan, and amivantamab show significant progression-free survival benefits
New Treatment Combinations Show Promise for Advanced Lung Cancer
This systematic review and meta-analysis of 3,606 patients evaluated 8 treatment strategies for advanced EGFR-mutant NSCLC. The analysis fou…
Specific drug combinations, including ivonescimab and amivantamab, show potential benefits for patients with advanced EGFR-mutant lung cance…
Chemoimmunotherapy improves objective response rate and survival in advanced pulmonary large-cell neuroendocrine carcinoma
Combining Chemotherapy and Immune Therapy Improves Outcomes for Advanced Lung Cancer
This meta-analysis of 3537 patients with advanced pulmonary large-cell neuroendocrine carcinoma (LCNEC) found that chemoimmunotherapy signif…
Adding an immune-boosting drug to standard chemotherapy helps patients with a specific type of advanced lung cancer live longer.
ctDNA and immune profiling offer a pathway toward individualized treatment for recurrent colorectal cancer
New tools help identify high risk of colorectal cancer relapse
This mini review explores ctDNA-guided surveillance, immune checkpoint blockade, and engineered cell therapies for patients with colorectal …
Doctors are using blood tests and immune profiling to better predict when colorectal cancer might return after treatment.
Immune checkpoint inhibitors plus chemotherapy improve overall survival in advanced triple-negative breast cancer
Immunotherapy plus chemo improves survival in triple-negative breast cancer
This umbrella meta-analysis of 39,147 patients found that combining immune checkpoint inhibitors with chemotherapy significantly improves ov…
Adding immunotherapy to chemo helps some patients with advanced triple-negative breast cancer live longer, but side effects are more common.
Multidisciplinary determination of resectability incorporates tumor biology and perioperative systemic therapy in stage III NSCLC
New Guidelines Redefine Surgery Options for Lung Cancer Patients
This clinical guideline addresses the management of stage III non-small cell lung cancer (NSCLC). It advocates for a multidisciplinary appro…
New guidelines suggest that surgery for certain lung cancers should be based on tumor biology and treatment response rather than just anatom…
First-line immune checkpoint inhibitor therapy improves progression-free survival and overall survival in MSI-H/dMMR mCRC
Immune checkpoint inhibitors improve survival for certain colorectal cancers
This meta-analysis of more than 600 patients with metastatic colorectal cancer (mCRC) involving microsatellite instability-high or mismatch …
New analysis shows immune checkpoint inhibitors offer better survival and fewer side effects than chemotherapy for specific types of metasta…